Santen Pharmaceutical Management
Management criteria checks 1/4
Santen Pharmaceutical's CEO is Takeshi Ito, appointed in Sep 2022, has a tenure of 2.17 years. total yearly compensation is ¥188.00M, comprised of 50% salary and 50% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth ¥138.33M. The average tenure of the management team and the board of directors is 3.3 years and 1.4 years respectively.
Key information
Takeshi Ito
Chief executive officer
JP¥188.0m
Total compensation
| CEO salary percentage | 50.0% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.02% |
| Management average tenure | 3.3yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | JP¥26b |
| Jun 30 2024 | n/a | n/a | JP¥27b |
| Mar 31 2024 | JP¥188m | JP¥94m | JP¥27b |
Compensation vs Market: Takeshi's total compensation ($USD1.22M) is above average for companies of similar size in the JP market ($USD926.78K).
Compensation vs Earnings: Insufficient data to compare Takeshi's compensation with company performance.
CEO
Takeshi Ito (65 yo)
2.2yrs
Tenure
JP¥188,000,000
Compensation
Mr. Takeshi Ito has been President and Chief Executive Officer at Santen Pharmaceutical Co., Ltd. since September 12, 2022 and serves as Representative Director since April 01, 2022. He served as Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.2yrs | JP¥188.00m | 0.024% ¥ 138.3m | |
| CFO & Corporate Officer | no data | no data | no data | |
| COO, Corporate Officer & Director | 1.7yrs | no data | 0.014% ¥ 83.4m | |
| General Manager of Investor Relations Group | no data | no data | no data | |
| General Counsel & Chief Compliance Officer | 4.1yrs | no data | no data | |
| Chief Communications Officer | 2.8yrs | no data | no data | |
| Corp. Officer | 3.8yrs | no data | no data | |
| Corporate Officer & Head of China Product Development Department | 10.6yrs | no data | no data | |
| Global Head of Core Principle & Sustainability and Corporate Officer | 2.8yrs | no data | no data | |
| Corporate Officer & Head of Supply Chain Division | 6.8yrs | no data | no data | |
| Head of R&D Strategic Operations | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
3.3yrs
Average Tenure
Experienced Management: 4536's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | JP¥188.00m | 0.024% ¥ 138.3m | |
| COO, Corporate Officer & Director | less than a year | no data | 0.014% ¥ 83.4m | |
| Corporate Officer | less than a year | no data | 0.0035% ¥ 20.0m | |
| Independent Outside Director | 2.4yrs | no data | 0.0014% ¥ 8.3m | |
| Chairman of the Board | 27.4yrs | JP¥171.00m | 0.068% ¥ 390.1m | |
| Outside Auditor | 1.4yrs | no data | 0.00087% ¥ 5.0m | |
| Independent Outside Director | less than a year | no data | no data | |
| Independent Outside Director | less than a year | no data | no data | |
| Standing Corporate Auditor | 4.4yrs | no data | 0.00029% ¥ 1.7m | |
| Outside Auditor | 1.4yrs | no data | no data | |
| Independent Outside Director | 2.4yrs | no data | no data | |
| Independent Outside Auditor | less than a year | no data | no data |
1.4yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 4536's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.